Nifty
Sensex
:
:
14677.80
48732.55
-18.70 (-0.13%)
41.75 (0.09%)

Pharmaceuticals & Drugs - Global

Rating :
46/99

BSE: 532523 | NSE: BIOCON

388.80
14-May-2021
  • Open
  • High
  • Low
  • Previous Close
  •  387.00
  •  392.90
  •  386.25
  •  385.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3423148
  •  13344.94
  •  487.75
  •  325.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 46,697.34
  • 63.06
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 48,324.14
  • N/A
  • 6.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 0.99%
  • 10.89%
  • FII
  • DII
  • Others
  • 16.3%
  • 7.11%
  • 4.04%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.62
  • 13.72
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.21
  • 10.50
  • 8.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 8.01
  • 30.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.89
  • 45.91
  • 55.57

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.60
  • 5.77
  • 6.32

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.35
  • 25.71
  • 27.21

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
1,838.70
1,557.50
18.05%
1,851.00
1,716.80
7.82%
1,744.80
1,567.30
11.33%
1,671.30
1,458.90
14.56%
Expenses
1,402.90
1,238.90
13.24%
1,451.50
1,272.60
14.06%
1,353.40
1,164.50
16.22%
1,258.00
1,021.40
23.16%
EBITDA
435.80
318.60
36.79%
399.50
444.20
-10.06%
391.40
402.80
-2.83%
413.30
437.50
-5.53%
EBIDTM
23.70%
20.46%
21.58%
25.87%
22.43%
25.70%
24.73%
29.99%
Other Income
205.40
63.10
225.52%
27.90
35.80
-22.07%
15.50
38.40
-59.64%
18.30
24.10
-24.07%
Interest
33.90
16.80
101.79%
4.80
17.70
-72.88%
6.50
13.80
-52.90%
12.50
16.60
-24.70%
Depreciation
184.30
152.40
20.93%
186.30
144.00
29.38%
177.70
131.60
35.03%
166.80
124.20
34.30%
PBT
435.60
212.50
104.99%
236.30
318.30
-25.76%
222.70
363.30
-38.70%
252.30
320.80
-21.35%
Tax
69.40
45.00
54.22%
48.90
84.80
-42.33%
22.30
100.10
-77.72%
80.90
85.20
-5.05%
PAT
366.20
167.50
118.63%
187.40
233.50
-19.74%
200.40
263.20
-23.86%
171.40
235.60
-27.25%
PATM
19.92%
10.75%
10.12%
13.60%
11.49%
16.79%
10.26%
16.15%
EPS
2.11
1.03
104.85%
1.41
1.69
-16.57%
1.41
1.80
-21.67%
1.25
1.72
-27.33%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
7,105.80
6,367.20
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,332.10
2,784.40
Net Sales Growth
12.78%
15.46%
33.73%
5.97%
16.24%
8.34%
7.39%
15.77%
6.57%
-16.24%
 
Cost Of Goods Sold
2,208.50
2,052.20
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
Gross Profit
4,897.30
4,315.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,480.10
2,059.00
GP Margin
68.92%
67.77%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
57.98%
63.47%
73.95%
Total Expenditure
5,465.80
5,110.20
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
Power & Fuel Cost
-
246.10
239.80
189.00
156.40
184.70
176.70
162.40
142.60
97.20
82.00
% Of Sales
-
3.87%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
5.74%
4.17%
2.94%
Employee Cost
-
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
389.40
307.60
238.80
% Of Sales
-
22.91%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
15.67%
13.19%
8.58%
Manufacturing Exp.
-
864.60
721.20
335.70
391.50
203.70
81.20
62.90
95.20
113.20
81.60
% Of Sales
-
13.58%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
3.83%
4.85%
2.93%
General & Admin Exp.
-
182.10
53.00
56.80
21.70
144.60
165.70
131.80
122.20
93.20
82.40
% Of Sales
-
2.86%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
4.92%
4.00%
2.96%
Selling & Distn. Exp.
-
270.30
277.50
98.20
107.40
100.80
108.70
118.90
99.60
89.40
62.40
% Of Sales
-
4.25%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
4.01%
3.83%
2.24%
Miscellaneous Exp.
-
36.10
37.20
47.40
41.00
50.00
72.70
61.80
52.90
256.70
62.40
% Of Sales
-
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
2.13%
11.01%
33.79%
EBITDA
1,640.00
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
539.00
522.80
571.00
EBITDA Margin
23.08%
19.74%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
21.69%
22.42%
20.51%
Other Income
267.10
507.50
414.30
206.20
157.10
83.90
53.10
55.90
56.70
63.80
57.10
Interest
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
8.10
12.40
24.30
Depreciation
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
179.30
175.80
156.70
PBT
1,146.90
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
408.30
398.40
447.10
Tax
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
97.50
55.90
72.10
Tax Rate
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
PAT
925.40
777.10
904.40
351.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
PAT before Minority Interest
819.70
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
Minority Interest
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
PAT Margin
13.02%
12.20%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
20.48%
14.65%
13.20%
PAT Growth
2.85%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
 
EPS
7.71
6.48
7.54
2.93
4.97
4.41
4.15
3.45
4.24
2.85
3.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
Share Capital
600.00
300.00
300.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
Total Reserves
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
Non-Current Liabilities
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
Secured Loans
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
Unsecured Loans
1.40
2.10
2.80
3.90
11.40
11.40
25.80
40.00
60.50
65.80
Long Term Provisions
85.80
66.10
49.30
36.00
29.90
15.00
7.80
4.00
0.00
1.00
Current Liabilities
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
Trade Payables
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
345.50
347.80
296.50
Other Current Liabilities
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
313.10
269.20
375.90
Short Term Borrowings
667.60
261.20
130.30
97.20
394.90
261.00
243.50
84.80
187.30
247.40
Short Term Provisions
230.90
204.30
135.60
143.20
133.90
158.20
176.60
246.50
211.50
140.80
Total Liabilities
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
Net Block
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
Gross Block
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
Accumulated Depreciation
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
Non Current Assets
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
Capital Work in Progress
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
Non Current Investment
108.50
182.50
63.80
188.80
26.80
0.00
64.50
64.50
64.20
60.90
Long Term Loans & Adv.
402.00
335.80
437.20
319.70
350.10
336.90
252.00
241.60
181.00
140.20
Other Non Current Assets
73.20
91.00
144.40
176.20
51.00
169.60
64.50
47.20
32.30
0.00
Current Assets
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
Current Investments
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
Inventories
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
398.40
378.30
413.70
Sundry Debtors
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
509.70
491.70
495.80
Cash & Bank
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
Other Current Assets
809.20
525.50
373.30
395.80
300.70
171.60
157.60
136.90
114.30
56.70
Short Term Loans & Adv.
265.60
153.10
54.70
24.10
134.70
75.80
81.80
81.40
37.10
20.20
Net Current Assets
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
Total Assets
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
471.20
564.10
798.50
PBT
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
610.20
395.20
447.10
Adjustment
921.40
472.60
355.70
204.40
42.00
74.00
134.00
147.30
144.80
163.50
Changes in Working Capital
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
-192.30
98.00
269.20
Cash after chg. in Working capital
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
565.20
638.00
879.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
-94.00
-73.90
-81.30
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
-375.80
-359.50
-314.50
Net Fixed Assets
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
Net Investments
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
Others
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
-200.00
-113.20
-112.27
Cash from Financing Activity
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
-8.60
-186.30
-274.60
Net Cash Inflow / Outflow
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
86.80
18.30
209.40
Opening Cash & Equivalents
659.30
449.00
710.20
757.50
457.50
557.00
474.00
369.00
359.00
139.90
Closing Cash & Equivalent
824.70
659.30
449.00
710.20
757.50
462.60
557.00
474.00
369.00
359.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
54.97
50.17
42.59
39.74
33.10
26.93
24.21
21.59
18.16
16.25
ROA
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
ROE
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
21.50%
16.59%
20.58%
ROCE
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
Fixed Asset Turnover
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.18
1.48
Receivable days
72.10
77.96
86.05
74.35
80.16
80.09
69.48
72.22
75.67
60.90
Inventory Days
70.72
58.05
60.00
54.81
53.71
48.47
48.54
56.01
60.69
50.77
Payable days
80.65
81.98
87.98
78.68
71.28
58.15
55.73
65.24
70.25
70.62
Cash Conversion Cycle
62.18
54.04
58.07
50.48
62.59
70.42
62.29
62.99
66.11
41.05
Total Debt/Equity
0.40
0.40
0.44
0.48
0.62
0.35
0.30
0.10
0.12
0.17
Interest Cover
19.72
18.12
10.57
33.05
25.90
71.12
317.29
76.33
33.13
19.40

News Update:


  • Biocon reports 92% rise in Q4 consolidated net profit
    29th Apr 2021, 11:32 AM

    Total income of the company increased by 26.13% at Rs 2044.10 crore for Q4FY21

    Read More
  • Biocon’s arm wins ISPE’s 2021 FOYA honorable mention award
    29th Apr 2021, 09:19 AM

    The company received an Honorable Mention award for its monoclonal antibodies drugs substances manufacturing facility

    Read More
  • Biocon’s arm receives European Commission approval for Biosimilar Bevacizumab
    26th Apr 2021, 09:44 AM

    The company has received approval following the positive recommendation by the CHMP of the European Medicines

    Read More
  • Biocon’s arm receives GMP compliance certificate from MHRA, UK
    12th Apr 2021, 10:28 AM

    The certificate was issued based on a remote inspection in the week of 22nd March, 2021

    Read More
  • Biocon’s arm inks pact with Libbs Farmaceutica
    30th Mar 2021, 08:59 AM

    The partnership aims to launch generic drugs in Brazil, the world's sixth most populous country

    Read More
  • Biocon incorporates wholly owned subsidiary company
    20th Mar 2021, 09:28 AM

    The company has incorporated a wholly owned subsidiary company namely ‘Biofusion Therapeutics’

    Read More
  • Biocon’s arm enters into partnership with International Diabetes Federation
    16th Feb 2021, 09:38 AM

    This important partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin

    Read More
  • Biocon’s arm, Viatris receive European Commission approval for Kixelle
    12th Feb 2021, 09:24 AM

    The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the EEA countries Iceland, Liechtenstein and Norway

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.